Changing Fortunes in the Generics Wars
Times may be a-changing for generics companies. Last month, Ivax won FDA approval for its generic version of Bristol-Myers Squibb's blockbuster cancer therapy Taxol.
You may also be interested in...
Biovail's stock plummeted recently after a sell recommendation from a highly-regarded Wall Street analyst--who's been accused of a conflict of interest for issuing it--and an FTC ruling on its alleged anti-competitive practices. The ruling, on late-listed Orange Book entries, will curtain common anti-generic strategies.
ARPA-H could be a solution to some of FDA’s long-running complaints about US clinical trial infrastructure, the agency's cancer chief says.
WM Partners acquires Vega plant-based nutrition brand from Danone with plans to leverage its operational experience to grow the brand and tap Vega’s distribution to expand market for its existing portfolio of brands.